Howe & Rusling Inc. Decreases Stake in Stryker Co. (NYSE:SYK)

Howe & Rusling Inc. cut its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 11.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,770 shares of the medical technology company's stock after selling 3,950 shares during the quarter. Howe & Rusling Inc.'s holdings in Stryker were worth $11,079,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. J. W. Coons Advisors LLC raised its position in Stryker by 0.7% during the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after acquiring an additional 26 shares in the last quarter. Mascoma Wealth Management LLC lifted its stake in shares of Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares during the period. Opal Wealth Advisors LLC boosted its holdings in Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after buying an additional 28 shares in the last quarter. Lindbrook Capital LLC grew its position in Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares during the period. Finally, Alhambra Investment Management LLC increased its holdings in Stryker by 1.5% in the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after buying an additional 29 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Finally, Canaccord Genuity Group increased their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $421.90.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Trading Down 0.9 %

Shares of SYK traded down $3.16 during midday trading on Friday, reaching $364.38. The company had a trading volume of 1,274,307 shares, compared to its average volume of 1,289,456. The firm has a 50 day simple moving average of $384.08 and a 200-day simple moving average of $374.32. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market cap of $139.08 billion, a PE ratio of 46.96, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the firm earned $3.46 EPS. Research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.